ArticleLeukemia2021
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Abstract read
In one paragraph
Article in Leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 1 pooled it
9.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.
- Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations.Bone marrow transplantation · 2025Guideline
- Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia.Frontiers in immunology · 2025Trial
- Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.Blood advances · 2023Trial
- Single-center phase 2 study of PD-1 inhibitor combined with DNA hypomethylation agent + CAG regimen in patients with relapsed/refractory acute myeloid leukemia.Cancer immunology, immunotherapy : CII · 2023Trial
- Hodgkin lymphoma: EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2026Article
- Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma: A Multicenter Real-World ExperienceTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study.Blood advances · 2026Article
- Immunotherapy for Melanoma in Patients with Altered Immune Systems: Unique Challenges and Clinical Considerations.Advances in therapy · 2026Review
- Engraftment syndrome after PD-1 blockade in classical Hodgkin lymphoma treated by autologous stem cell transplantation.International journal of hematology · 2026Article
- Reduced incidence of relapse after checkpoint inhibitors relative to brentuximab vedotin as salvage therapy before allogeneic stem cell transplantation for refractory/relapsed Hodgkin lymphoma: A retrospective analysis.British journal of haematology · 2025Article
- Impact of Novel Agents on Allogeneic Hematopoietic Cell Transplantation in Patients with T-Cell Lymphomas.Cells · 2025Review
- Article
- GVHD in the era of checkpoint inhibition in Hodgkin lymphoma.Blood advances · 2025Article
- Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma.Blood advances · 2025Article
- When to use stem cell transplantation for classical Hodgkin lymphoma.Hematology. American Society of Hematology. Education Program · 2024Review
- Has PD-1 blockade changed the standard of care for cHL?Hematology. American Society of Hematology. Education Program · 2024Review
- Review
- Article
- GVHD like skin eruption post-autologous stem cell transplantation.Bone marrow transplantation · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
66 authors at 20 institutions in 4 countries.
Reid W Merryman *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Reid_merryman@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-6360-3234
Luca Castagna *Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.
Laura GiordanoDepartment of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.
Vincent T HoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Paolo CorradiniDivision of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
Anna GuidettiDivision of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy.
Beatrice CasadeiIstituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università Degli Studi, Bologna, Italia.
David A BondDivision of Hematology, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0003-0773-1829
Samantha JaglowskiDivision of Hematology, The Ohio State University, Columbus, OH, USA.ORCID http://orcid.org/0000-0002-4335-2554
Michael A SpinnerDepartment of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Sally AraiDepartment of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Robert LowskyDepartment of Medicine, Stanford University Medical Center, Stanford, CA, USA.
Gunjan L ShahDepartment of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-9977-0456
Miguel-Angel PeralesDepartment of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID http://orcid.org/0000-0002-5910-4571
Jean Marc Schiano De ColellaProgramme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France.ORCID http://orcid.org/0000-0001-9923-4808
Didier BlaiseInstitut Paoli-Calmettes, Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.ORCID http://orcid.org/0000-0002-5684-9447
Alex F HerreraDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Geoffrey ShouseDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.ORCID http://orcid.org/0000-0002-7917-5713
Chloe SpilleboudtService Hématologie, Institut Bordet, Bruxelles, Belgium.
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0003-1244-6758
Yago NietoDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA.
Talha BadarDivision of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA.
Mehdi HamadaniBMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0001-5372-510X
Tatyana A FeldmanJohn Theurer Cancer Center at HMH, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA.
Lori DahnckeJohn Theurer Cancer Center at HMH, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA.
Anurag K SinghDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.
Joseph P McGuirkDivision of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA.ORCID http://orcid.org/0000-0002-0539-4796
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.ORCID http://orcid.org/0000-0002-2621-7924
Julio ChavezDepartment of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA.
Anthony V SerritellaDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Justin KlineDepartment of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA.
Mohamad MohtyService d'Hématologie Clinique et de Thérapie Cellulaire, Hospital Saint Antoine, Sorbonne University, Paris, France.
Remy DuleryDepartment of Hematology, Centre Henri Becquerel, Rouen, France.ORCID http://orcid.org/0000-0002-5024-1713
Aspasia StamatoulasDepartment of Hematology, Centre Henri Becquerel, Rouen, France.
Roch HouotDepartment of Hematology, CHU Rennes, University of Rennes, Inserm U1236, Rennes, France.
Guillaume MansonDepartment of Hematology, CHU Rennes, University of Rennes, Inserm U1236, Rennes, France.
Marie-Pierre Moles-MoreauCHU Angers, Angers, France.
Corentin OrvainCHU Angers, Angers, France.
Kamal BouabdallahHematology Clinic, University Hospital of Bordeaux, Pessac, France.
Dipenkumar ModiDepartment of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA.ORCID http://orcid.org/0000-0001-6525-8844
Radhakrishnan RamchandrenDivision of Hematology/Oncology, University of Tennessee School of Medicine, Knoxville, TN, USA.
Lazaros LekakisDivision of Transplantation and Cellular Therapy, University of Miami/Sylvester Cancer Center, Miami, FL, USA.
Amer BeitinjanehDivision of Transplantation and Cellular Therapy, University of Miami/Sylvester Cancer Center, Miami, FL, USA.
Matthew J FrigaultBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.
Yi-Bin ChenBlood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9554-1058
Ryan C LynchUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Stephen D SmithUniversity of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Uttam RaoDepartment of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Michael ByrneDepartment of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.
Jason T RomancikEmory University Winship Cancer Institute, Atlanta, GA, USA.
Jonathon B CohenEmory University Winship Cancer Institute, Atlanta, GA, USA.
Sunita NathanSection of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-7920-4265
Tycel PhillipsDivision of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA.
Robin M JoyceDivision of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Maryam RahimianDivision of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Asad BasheyBlood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA.
Hatcher J BallardDivision of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Jakub SvobodaDivision of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Valter TorriLaboratory of Methodology of Clinical Research, Oncology Department. IRCCS Mario Negri Institute, Milano, Italy.
Martina SolliniAzienda Ospedaliero-Universitaria di Bologna, Bologna, Italia.
Chiara De PhilippisDepartment of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.
Massimo MagagnoliDepartment of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.
Armando SantoroDepartment of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.
Philippe Armand *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6098-1603
Pier Luigi Zinzani *Istituto di Ematologia "Seràgnoli", Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università Degli Studi, Bologna, Italia.ORCID http://orcid.org/0000-0002-2112-2651
Carmelo Carlo-Stella *Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.ORCID http://orcid.org/0000-0003-3144-0124
Humanitas University · ITDana-Farber Cancer Institute · USStanford Medicine · USBeth Israel Deaconess Medical Center · USCentre Hospitalier Universitaire d'Angers · FRCentre Virchow-Villermé · FRCity of Hope · USEmory University · USHackensack Meridian Health · USHospital of the University of Pennsylvania · USInserm · FRIstituto di Ematologia di Bologna · ITMassachusetts General Hospital · USMemorial Sloan Kettering Cancer Center · USMoffitt Cancer Center · USThe Ohio State University · USUniversity of Chicago · USUniversity of Kansas Medical Center · USUniversity of Miami · USUniversity of Milan · IT
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MT LYMPHOCYTE SUBSET FUNCTION POST-TRANSPLANTATIONP01CA023766 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SCHEINBERG, DAVID A · 1985 to 2023
$59.0MNCI NIH HHS P01 CA023766NCI NIH HHS P30 CA008748
Abstract
Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent alloHCT after PD-1 blockade. With a median follow-up among survivors of 24 months, the 2-year cumulative incidences (CIs) of non-relapse mortality and relapse were 14 and 18%, respectively; the 2-year graft-versus-host disease (GVHD) and relapse-free survival (GRFS), progression-free survival (PFS), and overall survival were 47%, 69%, and 82%, respectively. The 180-day CI of grade 3-4 acute GVHD was 15%, while the 2-year CI of chronic GVHD was 34%. In multivariable analyses, a longer interval from PD-1 to alloHCT was associated with less frequent severe acute GVHD, while additional treatment between PD-1 and alloHCT was associated with a higher risk of relapse. Notably, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis was associated with significant improvements in PFS and GRFS. While awaiting prospective clinical trials, PTCy-based GVHD prophylaxis may be considered the optimal transplantation strategy for this patient population.
Indexed as
Drug Resistance, NeoplasmSalvage TherapyAdolescentAdultAgedFemaleFollow-Up StudiesHematopoietic Stem Cell TransplantationHodgkin DiseaseHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasm Recurrence, LocalPrognosisProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.